Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2022-03-25 00:00:00 ET · period of report 2022-03-23 · accession 0001714899-22-000061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-03-25 | 2022-03-23 | DNLI | Tessier-Lavigne Marc | Dir | S - Sale | $33.83 | -20.0K | 2.02M | -1.0% | -$676.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-23 | S | D | 8,402 | $33.40 | 2,035,968 | D | — | — | (F1) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.76 to $33.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F2) Includes 2,074 restricted stock units. |
| 2 | Common | Common Stock | 2022-03-23 | S | D | 11,598 | $34.14 | 2,024,370 | D | — | — | (F3) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.76 to $34.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F2) Includes 2,074 restricted stock units. |